Tumor Ablation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The tumor ablation market size is projected to expand from USD 1.76 billion in 2025 and USD 1.94 billion in 2026 to USD 3.14 billion by 2031, registering a CAGR of 10.20% between 2026 to 2031. This report is Segmented by Technology (Radiofrequency Ablation, Microwave Ablation, and More), Mode of Treatment (Surgical Ablation, Laparoscopic Ablation, and More), Application (Liver Cancer, Lung Cancer, and More), End User (Hospitals, Cancer Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Tumor Ablation Market Trends and Insights

Growing Cancer Incidence & Prevalence

Global diagnoses for liver, lung, and kidney cancers continue to climb, intensifying demand for focal therapies that spare organ function. The GLOBOCAN 2024 update logged 2.5 million new liver-cancer cases 6% higher than 2022, concentrated in hepatitis-B-endemic East Asia and sub-Saharan Africa. Lung cancer rose to 2.4 million cases in 2024, driven by persistent smoking and urban radon exposure. Kidney cancer reached 430,000 global cases; small renal masses under 4 cm are now routinely managed by percutaneous cryoablation to preserve nephrons. Prostate cancer exceeded 1.4 million cases, and focal high-intensity focused ultrasound (HIFU) is gaining traction for intermediate-risk disease. Collectively, these epidemiologic trends expand the tumor ablation market by creating larger cohorts unsuitable for resection or systemic therapy.

Demand for Minimally Invasive Surgeries

Payers prioritize shorter stays and lower complication rates, driving hospitals to adopt percutaneous and laparoscopic techniques. A 2024 JAMA Surgery study showed that percutaneous radiofrequency ablation (RFA) for colorectal liver metastases reduced median length of stay to 1.2 days from 5.8 days for hepatectomy and saved USD 12,000 per case. Robotic single-port thoracic ablation halved postoperative pain compared with video-assisted thoracoscopic surgery. Laparoscopic microwave ablation achieved 5-year local progression below 8% in early-stage hepatocellular carcinoma, rivaling resection outcomes. Patient surveys indicate 68% of candidates for small renal masses prefer ablation over surgery, citing faster recovery. These findings enlarge the tumor ablation market by persuading clinicians and payers to shift volume from open surgery.

Stringent Regulatory Approval Pathways & High Capital Cost

The European Union Medical Device Regulation (MDR) that took full effect in May 2024 compels post-market clinical follow-up and periodic safety reporting, adding 12-18 months to CE marking and inflating compliance costs significantly. Notified-body bottlenecks stretch reviews to 24 months, delaying revenue for mid-tier firms. Capital hurdles intensify the challenge: a turnkey histotripsy suite surpasses USD 1.5 million, while IRE and HIFU systems range from USD 400,000 to USD 1.2 million. Hospitals need 80+ procedures yearly to break even within five years, an unattractive proposition without guaranteed reimbursement. These cost-regulatory combinations slow device deployment and temporarily temper tumor ablation market velocity.

Other drivers and restraints analyzed in the detailed report include:

• Device Technology Innovations & AI-Guided Ablation
• Reimbursable Expansion of Non-Thermal Modalities & Local Manufacturing Incentives
• Reimbursement Gaps & Workforce Skill Shortages

Segment Analysis

Radiofrequency systems retained a 33.1% tumor ablation market share in 2025, supported by decades of evidence and established CPT codes. Nevertheless, histotripsy leads segment growth with an 11.4% CAGR, reflecting clinician demand for non-thermal approaches that avoid heat-sink effects near vessels. Microwave ablation overcomes perfusion cooling by achieving intratumoral temperatures above 100 °C and captured further share through Medtronic’s Emprint HP platform. Cryoablation appeals in renal and breast indications because ice-ball boundaries are visible on CT and ultrasound, facilitating precise margins.

As capital budgets migrate toward multi-modality rooms, hospitals evaluate lifetime costs across thermal and mechanical systems. Histotripsy’s ability to treat tumors within 5 mm of vital structures widens clinical candidacy and elevates procedure reimbursement, reinforcing its rapid uptake. In aggregate, these dynamics sustain robust growth while gradually diversifying the modality mix within the tumor ablation market.

Percutaneous procedures dominated 46.1% of volumes in 2025 and remain the workhorse for hepatocellular carcinoma and small renal masses. Robotic and endoluminal systems, however, are rising at an 11.1% CAGR as hospitals invest in electromagnetic navigation and single-port access to cut recovery time. The Monarch robotic bronchoscopy platform delivers microwave probes to peripheral lung nodules through natural airways, lowering chest-tube complications to under 2%. Hybrid operating rooms that combine fixed CT gantries with robotic arms enable diagnosis and ablation in a single session, reducing patient cycle time and driving higher throughput. These workflow gains expand the tumor ablation market size for advanced access solutions.

Complete Report Scope:

• By Technology
  • Radiofrequency (RF) Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation
  • High-Intensity Focused Ultrasound (HIFU)
  • Histotripsy
• By Mode of Treatment
  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation
  • Robotic / Endoluminal Ablation
• By Application
  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Bone Metastasis
  • Prostate Cancer
  • Breast & Soft-Tissue Tumors
  • Other Cancers (incl. Pancreas, Bladder, Brain)
• End User
  • Hospitals
  • Cancer Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 42.1% of revenue in 2025, anchored by 1.9 million annual cancer diagnoses, 400 fellowship graduates each year, and Medicare coverage for established modalities. The January 2024 CPT 0686T code for histotripsy accelerated hospital purchasing committees, and private insurers in 15 states issued policies within 18 months. Canada is piloting bundled payments to shift 30% of hepatocellular cases from surgery to percutaneous ablation by 2027, while Mexico’s social-security agency procured 50 microwave units in 2025 to clear treatment backlogs.

Asia-Pacific is forecast to grow at an 11.4% CAGR and is the primary arena for manufacturing incentives. India’s INR 50 billion subsidy lowers domestic device prices by 35%. China’s 14 local manufacturers launched RFA and microwave platforms in 2024, prompting Siemens Healthineers and Medtronic to localize production to protect share. Japan reimbursed IRE for pancreatic tumors in 2025, and South Korea invested KRW 120 billion in regional histotripsy hubs. These initiatives collectively expand the tumor ablation market across Asia’s large patient base.

Europe benefits from the EU Beating Cancer Plan, which earmarked EUR 4 billion for oncology modernization, including ablation suites. Germany’s statutory insurers added histotripsy to benefits in 2025, triggering orders at major university hospitals. The U.K.’s National Health Service is piloting microwave ablation for colorectal liver metastases to cut surgical waitlists by 15%. Middle East & Africa and South America remain nascent but are leveraging international finance facilities and local-content rules to accelerate device uptake, gradually enlarging their share of the tumor ablation market.

List of Companies Covered in this Report:

• Accuray
• AngioDynamics
• Boston Scientific
• EDAP TMS SA
• Elekta
• Emblation Ltd.
• Histosonics Inc.
• IceCure Medical Ltd.
• Insightec Ltd.
• Integra LifeSciences
• Johnson & Johnson (NeuWave Medical)
• Medtronic
• Merit Medical Systems
• Novocure Ltd.
• Olympus
• Siemens Healthineers
• STARmed Co., Ltd.
• Stryker
• Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support